[go: up one dir, main page]

WO1992002819A3 - Analyse permettant de rechercher la rectocolite hemorragique et l'angiocholite sclerosante primitive - Google Patents

Analyse permettant de rechercher la rectocolite hemorragique et l'angiocholite sclerosante primitive Download PDF

Info

Publication number
WO1992002819A3
WO1992002819A3 PCT/US1991/005276 US9105276W WO9202819A3 WO 1992002819 A3 WO1992002819 A3 WO 1992002819A3 US 9105276 W US9105276 W US 9105276W WO 9202819 A3 WO9202819 A3 WO 9202819A3
Authority
WO
WIPO (PCT)
Prior art keywords
ulcerative colitis
sclerosing cholangitis
primary sclerosing
assay
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1991/005276
Other languages
English (en)
Other versions
WO1992002819A2 (fr
Inventor
Stephan R Targan
Fergus L J Shanahan
Carol J Landers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of WO1992002819A2 publication Critical patent/WO1992002819A2/fr
Publication of WO1992002819A3 publication Critical patent/WO1992002819A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/554—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Physiology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Cette invention concerne un procédé permettant de déceler la présence de certaines maladies chez un patient, telles que la rectocolite hémorragique ou l'angiocholite sclérosante primitive. Le procédé consiste à mettre en contact un échantillon corporel du patient avec des neutrophiles immobilisés pour que les anticorps cytoplasmiques anti-neutrophiles se fixent aux neutrophiles. En outre, le procécé permet de détecter des anticorps cytoplasmiques anti-neutrophiles liés dont la présence indique un état pathologique.
PCT/US1991/005276 1990-08-10 1991-07-25 Analyse permettant de rechercher la rectocolite hemorragique et l'angiocholite sclerosante primitive Ceased WO1992002819A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56605190A 1990-08-10 1990-08-10
US566,051 1990-08-10

Publications (2)

Publication Number Publication Date
WO1992002819A2 WO1992002819A2 (fr) 1992-02-20
WO1992002819A3 true WO1992002819A3 (fr) 1992-03-19

Family

ID=24261265

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/005276 Ceased WO1992002819A2 (fr) 1990-08-10 1991-07-25 Analyse permettant de rechercher la rectocolite hemorragique et l'angiocholite sclerosante primitive

Country Status (1)

Country Link
WO (1) WO1992002819A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9211176D0 (en) * 1992-05-27 1992-07-08 Central Blood Lab Authority Assay
US5830675A (en) * 1993-03-10 1998-11-03 Cedars-Sinai Medical Center Methods for selectively detecting perinuclear anti-neutrophil cytoplasmic antibody of ulcerative colitis, primary sclerosing cholangitis, or type 1 autoimmune hepatitis
ATE193601T1 (de) * 1993-03-10 2000-06-15 Cedars Sinai Medical Center Verfahren zum selektiven nachweis von perinuklearen anti-neutrophilen cytoplasmischen antikörpern bei ulzerativen kolitis oder primärer sclerotischer cholangitis
US5681699A (en) * 1994-02-11 1997-10-28 Cedars-Sinai Medical Center Methods of diagnosing ulcerative colitis and Crohn's disease
US6884590B1 (en) 1994-02-11 2005-04-26 Cedars-Sinai Medical Center Methods of screening for ulcerative colitis and crohn's disease
US5738847A (en) * 1994-09-19 1998-04-14 The Regents Of The University Of California Anti-VH3-15 reagents and methods for their use
US5691151A (en) * 1994-10-07 1997-11-25 Regents Of University Of California Methods of screening for ulcerative colitis and crohn's disease by detecting VH3-15 autoantibody and panca
RU2141661C1 (ru) * 1998-11-18 1999-11-20 Московский медицинский стоматологический институт Способ лечения язвенной болезни
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
US9580752B2 (en) 2008-12-24 2017-02-28 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy
KR20230109779A (ko) 2013-03-27 2023-07-20 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한섬유증 및 염증의 완화 및 반전
EP3022295A4 (fr) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signature de la voie de signalisation de tl1a (tnfsf15)
EP3121289A1 (fr) 2015-07-22 2017-01-25 Humanitas Mirasole S.p.A. Micro-arn comme biomarqueurs de maladies biliaires
KR20220153109A (ko) 2016-03-17 2022-11-17 세다르스-신나이 메디칼 센터 Rnaset2를 통한 염증성 장 질환의 진단 방법

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CLINICAL AND EXPERIMENTAL IMMUNOLOGY vol. 76, 1989, OXFORD UK pages 30 - 33; J.A. SNOOK ET AL.: 'Anti-neutrophil nuclear antibody in ulcerative colitis, Crohns disease and primary sclerosing cholangitis.' See whole article. *
GASTROENTEROLOGY vol. 100, no. 6, 1 September 1991, WASHINGTON DC USA pages 1590 - 1599; R.H. DUERR ET AL.: 'Anti-neutrophil cytoplasmic antibodies in ulcerative colitis.' See whole article., *
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY vol. 86, no. 2, 1 August 1990, PHILADELPHIA PA USA pages 202 - 210; A. SAXON ET AL.: 'A distinct subset of antineutrophil cytoplasmic antibodies is assiciated with inflammatory bowel disease.' See whole article. *

Also Published As

Publication number Publication date
WO1992002819A2 (fr) 1992-02-20

Similar Documents

Publication Publication Date Title
WO1992002819A3 (fr) Analyse permettant de rechercher la rectocolite hemorragique et l'angiocholite sclerosante primitive
AU5799898A (en) Method for improving the recovery of troponin i and t
CA2000545A1 (fr) Procede et reactif pour la determination d'une substance pouvant etre particulierement liaisonnee
EE200300128A (et) Meetod allergeeniga seostuva immunoglobuliini detekteerimiseks proovis, patsiendi allergiate in vitro diagnoosimeetod, mikromaatrikskiip ja komplekt
WO1998018826A3 (fr) Anticorps anti-ccr5 et procedes d'utilisation correspondants
WO2000005265A3 (fr) Anticorps anti-ccr2 et procedes d'utilisation correspondants
ES2009939A6 (es) Un inmunoensayo para la deteccion simultanea de antigenos yno anticuerpos en una muestra a ensayar de un fluido fisiologico.
ES2131690T3 (es) Dispositivo para la dosificacion de haptenos y su utilizacion.
FI2645106T4 (fi) Menetelmiä terapeuttisen aineen aikaansaaman immuunivasteen arvioimiseksi
WO2001016184A3 (fr) Dosage de diagnostic pour la thrombocytopenie induite par l'heparine de type 2
CA2349274A1 (fr) Essai pour anticorps anti-transglutaminases
WO2003046140A3 (fr) Dosage immunologique et kit de detection precoce et simultanee de marqueurs biochimiques dans l'echantillon d'un patient
FI944225L (fi) Diagnostisia reagensseja EBV:n vasta-aineiden detektoimiseksi
CA2366514A1 (fr) Utilisation a des fins diagnostiques et therapeutiques d'anticorps diriges contre le recepteur de l'urokinase
CA2417161A1 (fr) Procede d'immunodetection d'epitopes
GB2307041B (en) Sheets,kits and methods for detecting antigens or antibodies
CA2043862A1 (fr) Determination des cobalamines
WO2001004633A3 (fr) Preparation de spheres pour essais diagnostics
EP1443328A3 (fr) Dosage de cobalamine
KR920703844A (ko) 사람에 있어 t-세포 표면 항원의 측정방법
IL108811A0 (en) Immunoassay reagents, kits and methods
WO1999001085A3 (fr) Antigene d'une maladie auto-immune de l'oreille interne et dosage diagnostique
EP0782863A4 (fr) Reactif anticorpal pour la detection des anevrismes dissequants de l'aorte et utilisation de ce reactif
EP0313005A3 (fr) Procédé pour la détection d'une maladie colorectale carcinomateuse et précarcinomateuse
AU6189486A (en) Monoclonal antibodies to prosomal proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE